Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

2C-D: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Oskykins
m Text replacement - "Temperature regulation loss" to "Temperature regulation suppression"
>Dutchmonster
m Add legality + citation for Netherlands, with a focus on a recent law that is a blanket ban
 
(153 intermediate revisions by 23 users not shown)
Line 1: Line 1:
{{proofread}}
{{SummarySheet}}
{{SubstanceBox/2C-D}}
{{SubstanceBox/2C-D}}
{|
|-
|-
| ''[[2C-D/Summary|Summary sheet: 2C-D]]''
|}
'''2C-D''' ('''2,5-dimethoxy-4-methylphenethylamine''', also known as '''2C-M''') is a [[psychedelic]] drug of the [[2C-x]] family that is sometimes used as an [[entheogen]]. It was first synthesized in 1970 by a team from the Texas Research Institute of Mental Sciences,<ref>https://www.ncbi.nlm.nih.gov/pubmed/5412084</ref> and its activity was subsequently investigated in humans by [[Alexander Shulgin]]<ref>Alexander Shulgin - PIHKAL | http://www.erowid.org/library/books_online/pihkal/pihkal033.shtml</ref>. The full name of the chemical is '''2,5-dimethoxy-4-methylphenethylamine'''. In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin lists the dosage range as being from 20 to 60 mg and many people recommend higher doses. Lower doses (generally 10 mg or less) of 2C-D have been explored as a potential nootropic, albeit with mixed results. 2C-D is generally taken orally, though may be insufflated (i.e., taken nasally). Insufflating tends to cause intense pain, however, and the dosage level is usually much lower, typically in the region of 1 to 15 mg.


Not much information is known about the toxicity of 2C-D, as no major studies have been conducted. According to Shulgin, the effects of 2C-D typically last for 4–6 hours. Shulgin himself referred to this substance as a “pharmacological tofu,” meaning that when mixed with other substances, it can extend or potentiate their effects without coloring the experience too much, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with. Some people have claimed 2C-D is relatively uninteresting on its own, but many other users have strongly disagreed with this assessment and believe that 2C-D is a true psychedelic in its own right.  
'''2,5-Dimethoxy-4-methylphenethylamine''' (also known as '''2C-M''', '''LE-25''' and more commonly as '''2C-D''') is a synthetic [[Psychoactive class::psychedelic]] of the [[Chemical class::phenethylamine]] chemical class that produces short-lived [[psychedelic]] effects when [[routes of administration|administered]]. Its sensory and cognitive effects profile has been described as being the most similar to that of [[mescaline]] among members of the [[2C-x family]], albeit with a significantly shorter duration.


In modern times, it is used as a recreational drug and an [[entheogen]], rarely sold on the streets and almost exclusively obtained as a grey area research chemical through the use of online vendors. Therefore, it is relatively uncommon and has only a short history of human use.
The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences.<ref name="Ho1970">{{cite journal|title=Amphetamine analogs. II. Methylated phenethylamines|pmid=5412084|doi=10.1021/jm00295a034|year=1970|volume=13|issue=1|pages=134-135|first1=B. T.|last1=Ho|first2=L. W.|last2=Tansey|first3=R. L.|last3=Balster|first4=R.|last4=An|first5=W. M.|last5=McIsaac|first6=R. T.|last6=Harris|journal=Journal of Medicinal Chemistry|issn=0022-2623|eissn=1520-4804|oclc=39480771}}</ref> Initial trials by [[Alexander Shulgin]] at sub-threshold doses in humans were carried out in 1964.<ref name="Shulgin1976">{{cite book|author=Alexander Shulgin|author-link=Alexander Shulgin|title=Pharmacology Notes I (The Shulgin Lab Books)|publisher=Erowid|url=https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf|page=176|place=Lafayette, CA|year=1976}}</ref>


Many users report that 2C-D is calmer and much more [[Sedation|sedating]] than other closely related [[psychedelic]] [[phenethylamine]]s.
Many anecdotal reports suggest that it is calmer, easier to handle and more comfortable on the body than other closely related [[psychedelic]] [[phenethylamines]]. While not especially visual or physically euphoric at common doses, it is reported to be very lucid, analytical and unimpaired in its headspace - a quality it retains even as the dose is increased.
 
Lower doses of 2C-D (generally 10 mg or less) have been explored for its use as a potential [[nootropic]], albeit with mixed results.<ref>{{cite web|author=Darrell Lemaire|year=1990|orig-year=Updated 2015|publisher=Erowid|url=https://www.erowid.org/chemicals/2cd/2cd_smartpills1.shtml|title=Certain Exotic Transmitters as Smart Pills or Compounds that Increase the Capacity for Mental Work in Humans|access-date=October 11, 2020}}</ref>
 
Today, 2C-D is used both recreationally and as an [[entheogen]]. It is rarely sold on the streets and almost exclusively distributed as a gray area [[research chemical]] by online vendors.
 
==History and culture==
The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences,<ref name="Ho1970"/>, but initial trials by [[Alexander Shulgin]] at sub-threshold doses were carried out in 1964. Further investigations at higher doses were carried out by Shulgin and his fellow researchers between 1974 and 1978.<ref name="Shulgin1976"/> The name '2C-D' derives from the chemical's structure - it is the 2-Carbon analogue of [[DOM]].
 
Shulgin notably referred to 2C-D as a “pharmacological tofu,” meaning it can extend or potentiate the effect of other substances without overly coloring the experience, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with.{{citation needed}} While some use this as evidence that 2C-D is relatively uninteresting as a psychedelic on its own, others strongly disagree with this assessment and hold that 2C-D is an unusually versatile and fully-fledged [[psychedelic]] in its own right.
 
Despite showing promise as a very functional psychostimulant<ref>{{cite journal|last1=Zuba|first1=D.|last2=Sekuła|first2=K.|year=2013|title=Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs|journal=Drug Testing and Analysis|volume=5|issue=8|pages=634–645|doi=10.1002/dta.1397|pmid=22936468|issn=1942-7603|eissn=1942-7611|oclc=231680670}}</ref><ref>{{cite journal|last1=King|first1=L. A.|year=2014|title=New phenethylamines in Europe|journal=Drug Testing and Analysis|volume=6|issue=7–8|pages=808–818|doi=10.1002/dta.1570|pmid=24574327|issn=1942-7603|eissn=1942-7611|oclc=231680670}}</ref> with successful studies investigating the use in psychotherapy in Germany,<ref>{{cite book|last1=Schneider|first1=U.|first2=D.E.|last2=Dietrich|first3=U.|last3=Gast|year=2004|title=Aspekte des Psychischen: Festschrift anlässlich des 60. Geburtstags von Hinderk M. Emrich|location=Würzbug, Germany|publisher=Königshausen & Neumann|language=de|isbn=3826027299|oclc=55887990}}</ref> 2C-D has not found widespread use. This has been argued to be due to the previously limited diversity of substances on the market - a consumer dynamic which has changed significantly with the advent of the internet - allowing a broader freedom of choice for explorers of psychedelic phenethylamines.<ref>{{cite book|author=James Martin|year=2014|doi=10.1057/9781137399052|title=Drugs on the Dark Net: How Cryptomarkets are Transforming the Global Trade in Illicit Drugs|isbn=978-1-349-48566-6|oclc=903145880|publisher=Palgrave Macmillan|location=Basingstoke, UK|series=Palgrave pivot.}}</ref> Of these, it tends to be substantially harder to find and notably more expensive by weight.{{citation needed}}


==Chemistry==
==Chemistry==
[[File:SubstitutedPhenethylamine.png|thumb|right|280px||General formula of phenethylamine molecule.]]
[[File:Phenethylamine.png|thumb|right|253px|thumb|right||Generic structure of a phenethylamine molecule]]
2C-D or 2,5-dimethoxy-4-methylphenethylamine is a substituted [[phenethylamines|phenethylamine]] featuring a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain. 2C-D contains methoxy functional groups CH<sub>3</sub>O- attached to carbons R<sub>2</sub> and R<sub>5</sub> as well as a methyl group attached to carbon R<sub>4</sub> of the phenyl ring. 2C-D belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring. <ref>http://isomerdesign.com/PiHKAL/read.php?id=22</ref>
2C-D, or 2,5-dimethoxy-4-methylphenethylamine, is a substituted [[phenethylamines|phenethylamine]] featuring a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain. 2C-D contains methoxy functional groups CH<sub>3</sub>O- attached to carbons R<sub>2</sub> and R<sub>5</sub> as well as a methyl group attached to carbon R<sub>4</sub> of the phenyl ring.  
 
2C-D belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.


==Pharmacology==
==Pharmacology==
{{Main|Serotonergic psychedelic}}
{{Further|Serotonergic psychedelic}}
2C-D's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT System|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]].  
2C-D's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]. However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.


However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
==Subjective effects==
The head space of 2C-D is described by many as being lucid, insightful and relatively normal in its thought processes even at moderate to high doses. The feeling of unaltered consciousness may be unsatisfying to users who want an intense experience because the head space is fairly normal, stable and therefore sometimes uninteresting to those who are new to hallucinogenic experiences.


==Subjective effects==
{{Preamble/SubjectiveEffects}}
The effects listed below are based upon the [[subjective effects index]] and personal experiences of [[PsychonautWiki]] [[Special:TopUsers|contributors]]. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.
{{effects/base
===Physical effects===
The physical effects of 2C-D can be broken down into several components which progressively intensify proportional to dosage. These are described below and generally include:


*'''[[Effect::Spontaneous tactile sensations]]''' -  The "body high" of 2C-D can be described as a pleasurable, all-encompassing comfort sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
|{{effects/physical|
*'''[[Effect::Sedation]]''' - In terms of its effects on the physical energy levels of the tripper, the 2C-D experience begins with mild sedation that increases as the trip progresses, and lacks the distinctive energetic feeling associated with most [[phenethylamines]].
*'''[[Effect::Stimulation]]''' - In terms of its effects on the physical energy levels of the user, the 2C-D experience begins with mild sedation that gives way to moderate stimulation as the experience progresses. It lacks the forceful energetic push associated with most psychedelic [[phenethylamines]].
*'''[[Effect::Nausea]]''' -  Although nausea remains present, in comparison to other [[phenethylamines]] such as [[2C-E]], [[2C-I]] or [[2C-B]], this remains extremely mild and dissipates quickly even with higher dosages. It is a very kind and mild [[psychedelic]] for this reason.
*'''[[Effect::Spontaneous physical sensations]]''' -  The "body high" of 2C-D can be described as a pleasurable, all-encompassing comfort sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
*'''[[Effect::Bodily control enhancement]]''' and '''[[Motor control loss]]''' - Whilst at lower doses one may find that their bodily control is enhanced, at higher dosages it seems to become suppressed.
*'''[[Effect::Bodily control enhancement]]''' - Whilst at lower doses one may find that their bodily control is enhanced, at higher dosages it seems to become suppressed.
*'''[[Effect::Tactile enhancement]]'''
*'''[[Effect::Tactile enhancement]]'''
*'''[[Effect::Temperature regulation suppression]]'''
*'''[[Effect::Temperature regulation suppression]]'''
*'''[[Effect::Increased heart rate]]'''
*'''[[Effect::Dehydration]]'''
*'''[[Effect::Nausea]]''' -  In comparison to other [[phenethylamines]] such as [[2C-E]], [[2C-I]] or [[2C-B]], any nausea produced by this substance tends to be very mild and dissipates quickly even with higher dosages.
*'''[[Effect::Pupil dilation]]'''
*'''[[Effect::Pupil dilation]]'''


===Cognitive effects===
}}
The head space of 2C-D is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages. The feeling of "unaltered consciousness" may be bothersome to trippers that are willing to experience events and concepts from a shifting point of view, since on 2C-D everything is fairly normal, stable and therefore rather uninteresting.
{{effects/visual|
 
Compared to other members of the 2C-x family like [[2C-B]], the visual effects of 2C-D have been noted for being understated until heavier doses are reached. After this point, a full spectrum of hallucinatory visual phenomena begin to appear.
The total sum of these cognitive components regardless of the setting generally includes:
 
*'''[[Effect::Analysis enhancement]]'''
*'''[[EFfect::Introspection]]'''
*'''[[Effect::Thought acceleration]]'''
*'''[[Effect::Time distortion]]'''
*'''[[Effect::Novelty enhancement]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Thought connectivity]]'''
*'''[[Effect::Current mind state enhancement]]'''
*'''[[Effect::Personal bias suppression]]'''
*'''[[Effect::Memory suppression]]'''
*'''[[Effect::Ego death]]'''
 
===Visual effects===
====Enhancements====
====Enhancements====
2C-D presents a full and complete array of possible visual enhancements which generally includes:
*'''[[Effect::Visual acuity enhancement|Acuity enhancement]]'''
*'''[[Effect::Colour enhancement]]'''
*'''[[Effect::Colour enhancement]]'''
*'''[[Effect::Pattern recognition enhancement]]'''
*'''[[Effect::Pattern recognition enhancement]]'''
*'''[[Effect::Visual acuity enhancement]]'''


====Distortions====
====Distortions====
2C-D presents a full and complete array of possible visual distortions which generally includes:
*'''[[Effect::Drifting]]''' ''([[Drifting#Melting|melting]], [[Drifting#Flowing|flowing]], [[Drifting#Breathing|breathing]] and [[Drifting#morphing|morphing]])'' - In comparison to other psychedelics, this effect can be described as low in detail, slow and smooth in motion, static in appearance and realistic in style.
*'''[[Effect::Drifting]]''' ''([[Drifting#Melting|melting]], [[Drifting#Flowing|flowing]], [[Drifting#Breathing|breathing]] and [[Drifting#morphing|morphing]])'' - In comparison to other psychedelics, this effect can be described as low in detail, slow and smooth in motion, static in appearance and realistic in style.
*'''[[Effect::Tracers]]'''
*'''[[Effect::Tracers]]'''
*'''[[Effect::After images]]'''
*'''[[Effect::Colour shifting]]'''
*'''[[Effect::Colour shifting]]'''
*'''[[Effect::Colour tinting]]'''
*'''[[Effect::Symmetrical texture repetition]]'''
*'''[[Effect::Recursion]]'''
*'''[[Effect::Diffraction]]'''


====[[effect::Geometry]]====
====[[effect::Geometry]]====
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of [[DOM]] or [[25D-NBOMe]] than that of [[LSD]], [[2C-B]] or [[2C-I]]. They can be comprehensively described as structured in their organization, organic in style, intricate in complexity, large in size, slow and smooth in motion, colourful in scheme, bright in colour, blurred in its edges and equally rounded and angular in its corners. They give off a natural feel to them at higher dosages. Whilst the final level of 2C-D geometry 2C-D has yet to be formally confirmed, it seems more likely that it would result in states of [[Effect::8B Geometry|Level 8B]] visual geometry over [[8A Geometry|Level 8A]].
The visual geometry of 2C-D be described as more similar in appearance to that of [[DOM]] or [[25D-NBOMe]] than that of [[LSD]], [[2C-B]] or [[2C-I]]. It can be comprehensively described as structured in its organization, organic in style, intricate in complexity, large in style, slow and smooth in motion, colorful in scheme, bright in color, blurred in its edges and equally rounded and angular in its corners. It gives off a natural feel at higher dosages. While the final level of 2C-D geometry has yet to be formally confirmed, it seems more likely that it would result in states of [[Effect::8B Geometry|level 8B]] visual geometry over [[8A Geometry|level 8A]].


====Hallucinatory states====
====Hallucinatory states====
2C-D produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. This holds particularly true in comparison to other substances within the [[phenethylamines|phenethylamine]] family. These effects include:
*'''[[Effect::Transformations]]'''
*'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - In comparison to other psychedelics such as [[LSD]], 2C-D is low in hallucinations embedded within visual geometry. However, when it does occur this particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They are more common within dark environments and can be described as internal in their manifestation, lucid in believability, and interactive in style.
*'''[[Effect::External hallucination]]''' (''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') -  2C-D is capable of external hallucinations embedded within visual geometry. This particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They can be described as external in their manifestation, lucid in believability, and fixed in style.


*'''[[Effect::Transformations]]'''
}}
*'''[[Effect::Internal hallucinations]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'') - In comparison to other psychedelics such as [[LSD]], 2C-D is low in hallucinations embedded within visual geometry. However, when it does occur this particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They are more common within dark environments and can be described as internal in their manifestation, lucid in believability, and interactive in style.
|{{effects/cognitive|
*'''[[Effect::External hallucinations]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'') -  2C-D is capable of external hallucinations embedded within visual geometry. This particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They can be described as external in their manifestation, lucid in believability, and fixed in style.
 
*'''[[Effect::Analysis enhancement]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Emotion enhancement]]'''
*'''[[Effect::Introspection]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Increased sense of humor]]'''
*'''[[Effect::Memory suppression]]'''
**'''[[Effect::Ego death]]'''
*'''[[Effect::Novelty enhancement]]'''
*'''[[Effect::Personal bias suppression]]'''
*'''[[Effect::Thought acceleration]]'''
*'''[[Effect::Thought connectivity]]'''
*'''[[Effect::Time distortion]]'''


===Auditory effects===
}}
The auditory effects of 2C-D are common in their occurrence and exhibit a full range of effects which commonly include:
{{effects/auditory|
*'''[[Effect::Auditory enhancement|Enhancements]]'''
*'''[[Effect::Auditory enhancement|Enhancements]]'''
*'''[[Effect::Auditory distortion|Distortions]]'''
*'''[[Effect::Auditory distortion|Distortions]]'''
*'''[[Effect::Auditory hallucination|Hallucinations]]'''
*'''[[Effect::Auditory hallucinations|Hallucinations]]'''
 
}}
{{effects/multisensory|
 
*'''[[Effect::Synaesthesia]]''' - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
 
}}
{{effects/transpersonal|
 
*'''[[Effect::Existential self-realization]]'''
*'''[[Effect::Unity and interconnectedness]]'''
 
}}
}}
===Experience reports===
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
 
*[https://erowid.org/experiences/subs/exp_2CD.shtml Erowid Experience Vaults: 2C-D]


==Toxicity and harm potential==
==Toxicity and harm potential==
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
The toxicity and long-term health effects of recreational 2C-D use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. This is because 2C-D is a [[research chemical]] with very little history of human usage.


===Lethal dosage===
Anecdotal evidence from those within the community who have tried 2C-D suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
The toxicity and long-term health effects of recreational 2C-D use do not seem to have been studied in any scientific context and the median lethal dose (LD50) is unknown. This is because 2C-D is a research chemical with very little history of human usage. Anecdotal evidence from those who have used 2C-D would suggest that there are little to no immediate or short-term negative health effects attributed to the consumption of the drug up to 50mgs. The validity of these statements, however, cannot be confirmed.


It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance.
===Tolerance and addiction potential===
===Tolerance and addiction potential===
The addictive potential of 2C-D has not yet been formally studied, but anecdotal evidence would suggest that 2C-D is not physically addictive.  
2C-D is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating.
 
Tolerance to the effects of 2C-D is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). 2C-D presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 2C-D all psychedelics will have a reduced effect.
 
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Psychedelics}}


Many users describe a self-regulating quality and commonly report a tolerance build up when using the drug consecutively many days in a row. A build up in tolerance may lead to weakened effects and a diminished experience, however, this effect is nearly non-existent when consumption periods are spaced 5-7 days apart.
==Legal status==


==Legal issues==
*'''Australia''': Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.<ref>{{cite web|title=Psychoactive Substances|publisher=National Drug and Alcohol Research Centre|year=2014|url=https://comorbidity.edu.au/sites/default/files/cre/page/New%20Psychoactive%20Substances.pdf}}{{dead link|date=October 2020}}</ref>
*'''United States:''' 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.<ref>S. 3187: Food and Drug Administration Safety and Innovation Act, Subtitle D-Synthetic Drugs | http://www.govtrack.us/congress/bills/112/s3187/text</ref>
*'''Austria''': 2C-D is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich). In its Schedule II, the further specifying NPSV (Neue-Psychoaktive-Substanzen-Verordnung Österreich) explicitly bans all substituted phenetylamines.<ref>{{cite web|url=https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=20007642|title=Bundesrecht konsolidiert: Gesamte Rechtsvorschrift für Neue-Psychoaktive-Substanzen-Verordnung|date=June 26, 2019|language=de|access-date=January 10, 2021}}</ref>
*'''United Kingdom:''' 2C-D is a Class A controlled substance as it is covered by the phenethylamine derivatives clause of the Misuse of Drugs Act of 1971.
*'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>{{cite web|url=http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7|title=RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016|publication-date=December 5, 2016|publisher=Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]|language=pt}}</ref>
*'''Sweden:''' 2C-D is classified as a "health hazard" as of March 1, 2005 in their regulation SFS 2005:26, making it illegal to sell or possess.<ref>Svensk författningssamling | http://www.notisum.se/rnp/sls/sfs/20050026.pdf</ref>
*'''Canada''': 2C-D would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>{{cite web|url=http://isomerdesign.com/Cdsa/schedule.php?schedule=3&section=ALL&structure=C|title=Schedule III|work=Controlled Drugs and Substances Act (CDSA)|publisher=Isomer Design|access-date=October 10, 2020}}</ref>
*'''Japan:''' 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell. <ref>Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical AŠairs Law in Japan, Part I: GC-MS and LC-MS | https://www.erowid.org/references/texts/show/7395docid7635</ref>
*'''China''': 2C-D is a controlled substance in China as of October 2015.<ref>{{cite web|url=http://www.sfda.gov.cn/WS01/CL0056/130753.html|title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知|publisher=国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]|date=September 27, 2015|language=zh|archive-url=https://web.archive.org/web/20170906191704/http://www.sfda.gov.cn/WS01/CL0056/130753.html|archive-date=September 6, 2017}}</ref>
*'''Australia:''' Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.<ref>New Psychoactive Substances (National Drug and Alcohol Research Centre 2014) | https://comorbidity.edu.au/sites/default/files/cre/page/New%20Psychoactive%20Substances.pdf</ref>
*'''Denmark''': 2C-D is added to the list of Schedule B controlled substances.<ref>{{cite web|url=https://www.retsinformation.dk/Forms/R0710.aspx?id=137169|title=Bekendtgørelse om euforiserende stoffer|access-date=December 10, 2019|language=da|id=BEK Nr. 557|date=May 31, 2011|publisher=Civilstyrelsen [Civil Agency]}}</ref>
*'''Denmark''': 2C-D is added to the list of Schedule B controlled substances.<ref>https://www.retsinformation.dk/Forms/R0710.aspx?id=137169</ref>
*'''Germany''': 2C-D is controlled under Anlage I BtMG (''Narcotics Act, Schedule I'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> as of December 13, 2014.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl114s1999.pdf|title=Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2014 Teil I Nr. 57|page=1999-2002|publication-date=December 12, 2014|language=de|oclc=231871244|issn=0341-1095|date=December 5, 2014}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: § 29|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref>
*'''Japan''': 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.<ref>{{cite journal|title=Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical Affairs Law in Japan, Part I: GC-MS and LC-MS|url=https://www.erowid.org/references/texts/show/7395docid7635|language=ja|volume=128|issue=6|pages=971-979|journal=Yakugaku Zasshi|eissn=0031-6903|issn=1347-5231|oclc=909890652|year=2008|pmid=18520145|doi=10.1248/yakushi.128.981|first1=N.|last1=Uchiyama|first2=M.|last2=Kawamura|first3=H.|last3=Kamakura|first4=R.|last4=Kikura-Hanajiri|first5=Y.|last5=Goda}}</ref>
*'''Latvia''': 2C-D is a Schedule I controlled substance.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref>
*'''The Netherlands:''' 2C-D is currently legal, but it is part of a substance group that may be banned soon as part of a recently passed law on New Psychoactive Substances (NPS). <ref>{{Citation|title= Wijziging van de Opiumwet in verband met het toevoegen van een derde lijst met als doel het tegengaan van de productie van en de handel in nieuwe psychoactieve stoffen en enkele andere wijzigingen (Dutch) | year=2024|url=https://www.tweedekamer.nl/kamerstukken/wetsvoorstellen/detail?id=2022Z14042&dossier=36159}}</ref>
*'''Sweden''': 2C-D is classified as a health hazard as of March 1, 2005, in the regulation SFS 2005:26, making it illegal to sell or possess.<ref>{{cite web|title=Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor|url=http://www.notisum.se/rnp/sls/sfs/20050026.pdf|id=SFS 2005:26|language=sv|date=February 3, 2005|publication-date=February 15, 2005|publisher=Läkemedelsverket [Swedish Medical Products Agency]|issn=1101-5225|work=Läkemedelsverkets författningssamling (LVFS)}}</ref>
*'''Switzerland''': 2C-D is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Turkey:''' 2C-D is a classed as drug and is illegal to possess, produce, supply, or import.<ref>Bakanlar Kurulu Kararı Karar Sayısı : 2013/4827 | https://free-ankara.org/wp-content/uploads/2017/09/BKK_2013_4827_28688.pdf</ref>
*'''United Kingdom''': 2C-D is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=August 20, 2020|publisher=UK Government}}</ref>
*'''United States''': 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.<ref>{{cite web|url=http://www.govtrack.us/congress/bills/112/s3187/text|title=S. 3187 (112<sup>th</sup>): Food and Drug Administration Safety and Innovation Act|date=June 27, 2012|access-date=October 10, 2020|publisher=GovTrack}}</ref>


==See also==
==See also==
*[[Responsible use]]
*[[Psychoactive substance index]]
*[[Psychoactive substance index]]
*[[Psychedelics]]
*[[Psychedelics]]
Line 109: Line 157:


==External links==
==External links==
*[http://en.wikipedia.org/wiki/2C-D 2C-D (Wikipedia)]
 
*[https://www.erowid.org/chemicals/2cd/2cd.shtml 2C-D (Erowid)]
*[https://en.wikipedia.org/wiki/2C-D 2C-D (Wikipedia)]
*[https://erowid.org/chemicals/2cd/2cd.shtml 2C-D (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=23 2C-D (PiHKAL / Isomer Design)]
 
===Forums===
 
*[http://www.bluelight.org/vb/threads/111481-The-Big-amp-Dandy-2C-D-Thread 2C-D (Bluelight)]


==References==
==References==
<references/>
{{reflist|2}}
{{#set:Featured=true}}
{{#set:Featured=true}}
[[Category:Psychoactive substances]]
 
[[Category:Phenethylamine]]
[[Category:Psychoactive substance]]
[[Category:Psychedelic]]
[[Category:Psychedelic]]
[[Category:2C-x]]

Latest revision as of 17:39, 18 January 2024

Summary sheet: 2C-D
2C-D
Chemical Nomenclature
Common names 2C-D, 2C-M, LE-25
Substitutive name 2,5-Dimethoxy-4-methylphenethylamine
Systematic name 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminoethane
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 3 mg
Light 10 - 25 mg
Common 25 - 50 mg
Strong 50 - 100 mg
Heavy 100 mg +
Duration
Total 3 - 5 hours
Onset 15 - 45 minutes
Come up 20 - 40 minutes
Peak 1.5 - 2.5 hours
Offset 0.5 - 1.5 hours
After effects 1 - 4 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions


2,5-Dimethoxy-4-methylphenethylamine (also known as 2C-M, LE-25 and more commonly as 2C-D) is a synthetic psychedelic of the phenethylamine chemical class that produces short-lived psychedelic effects when administered. Its sensory and cognitive effects profile has been described as being the most similar to that of mescaline among members of the 2C-x family, albeit with a significantly shorter duration.

The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences.[1] Initial trials by Alexander Shulgin at sub-threshold doses in humans were carried out in 1964.[2]

Many anecdotal reports suggest that it is calmer, easier to handle and more comfortable on the body than other closely related psychedelic phenethylamines. While not especially visual or physically euphoric at common doses, it is reported to be very lucid, analytical and unimpaired in its headspace - a quality it retains even as the dose is increased.

Lower doses of 2C-D (generally 10 mg or less) have been explored for its use as a potential nootropic, albeit with mixed results.[3]

Today, 2C-D is used both recreationally and as an entheogen. It is rarely sold on the streets and almost exclusively distributed as a gray area research chemical by online vendors.

History and culture

The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences,[1], but initial trials by Alexander Shulgin at sub-threshold doses were carried out in 1964. Further investigations at higher doses were carried out by Shulgin and his fellow researchers between 1974 and 1978.[2] The name '2C-D' derives from the chemical's structure - it is the 2-Carbon analogue of DOM.

Shulgin notably referred to 2C-D as a “pharmacological tofu,” meaning it can extend or potentiate the effect of other substances without overly coloring the experience, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with.[citation needed] While some use this as evidence that 2C-D is relatively uninteresting as a psychedelic on its own, others strongly disagree with this assessment and hold that 2C-D is an unusually versatile and fully-fledged psychedelic in its own right.

Despite showing promise as a very functional psychostimulant[4][5] with successful studies investigating the use in psychotherapy in Germany,[6] 2C-D has not found widespread use. This has been argued to be due to the previously limited diversity of substances on the market - a consumer dynamic which has changed significantly with the advent of the internet - allowing a broader freedom of choice for explorers of psychedelic phenethylamines.[7] Of these, it tends to be substantially harder to find and notably more expensive by weight.[citation needed]

Chemistry

Generic structure of a phenethylamine molecule

2C-D, or 2,5-dimethoxy-4-methylphenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-D contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as a methyl group attached to carbon R4 of the phenyl ring.

2C-D belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.

Pharmacology

Further information: Serotonergic psychedelic

2C-D's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The head space of 2C-D is described by many as being lucid, insightful and relatively normal in its thought processes even at moderate to high doses. The feeling of unaltered consciousness may be unsatisfying to users who want an intense experience because the head space is fairly normal, stable and therefore sometimes uninteresting to those who are new to hallucinogenic experiences.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Multi-sensory effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 2C-D use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-D is a research chemical with very little history of human usage.

Anecdotal evidence from those within the community who have tried 2C-D suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

2C-D is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 2C-D is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 2C-D presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 2C-D all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • [[Wikipedia:Lithium_(medication)|DangerousInteraction::Lithium]] - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of 2C-D. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.[citation needed]
  • "[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Tramadol is well-documented to lower the seizure threshold[8] and psychedelics may act to trigger seizures in susceptible individuals.[citation needed]
  • Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.[9]
  • Austria: 2C-D is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich). In its Schedule II, the further specifying NPSV (Neue-Psychoaktive-Substanzen-Verordnung Österreich) explicitly bans all substituted phenetylamines.[10]
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[11]
  • Canada: 2C-D would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[12]
  • China: 2C-D is a controlled substance in China as of October 2015.[13]
  • Denmark: 2C-D is added to the list of Schedule B controlled substances.[14]
  • Germany: 2C-D is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[15] as of December 13, 2014.[16] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[17]
  • Japan: 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.[18]
  • Latvia: 2C-D is a Schedule I controlled substance.[19]
  • The Netherlands: 2C-D is currently legal, but it is part of a substance group that may be banned soon as part of a recently passed law on New Psychoactive Substances (NPS). [20]
  • Sweden: 2C-D is classified as a health hazard as of March 1, 2005, in the regulation SFS 2005:26, making it illegal to sell or possess.[21]
  • Switzerland: 2C-D is a controlled substance specifically named under Verzeichnis E.[22]
  • Turkey: 2C-D is a classed as drug and is illegal to possess, produce, supply, or import.[23]
  • United Kingdom: 2C-D is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.[24]
  • United States: 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.[25]

See also

Forums

References

  1. 1.0 1.1 Ho, B. T.; Tansey, L. W.; Balster, R. L.; An, R.; McIsaac, W. M.; Harris, R. T. (1970). "Amphetamine analogs. II. Methylated phenethylamines". Journal of Medicinal Chemistry. 13 (1): 134–135. doi:10.1021/jm00295a034. eISSN 1520-4804. ISSN 0022-2623. OCLC 39480771. PMID 5412084. 
  2. 2.0 2.1 Alexander Shulgin (1976). Pharmacology Notes I (The Shulgin Lab Books) (PDF). Lafayette, CA: Erowid. p. 176. 
  3. Darrell Lemaire (1990) [Updated 2015]. "Certain Exotic Transmitters as Smart Pills or Compounds that Increase the Capacity for Mental Work in Humans". Erowid. Retrieved October 11, 2020. 
  4. Zuba, D.; Sekuła, K. (2013). "Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs". Drug Testing and Analysis. 5 (8): 634–645. doi:10.1002/dta.1397. eISSN 1942-7611. ISSN 1942-7603. OCLC 231680670. PMID 22936468. 
  5. King, L. A. (2014). "New phenethylamines in Europe". Drug Testing and Analysis. 6 (7–8): 808–818. doi:10.1002/dta.1570. eISSN 1942-7611. ISSN 1942-7603. OCLC 231680670. PMID 24574327. 
  6. Schneider, U.; Dietrich, D.E.; Gast, U. (2004). Aspekte des Psychischen: Festschrift anlässlich des 60. Geburtstags von Hinderk M. Emrich (in Deutsch). Würzbug, Germany: Königshausen & Neumann. ISBN 3826027299. OCLC 55887990. 
  7. James Martin (2014). Drugs on the Dark Net: How Cryptomarkets are Transforming the Global Trade in Illicit Drugs. Palgrave pivot. Basingstoke, UK: Palgrave Macmillan. doi:10.1057/9781137399052. ISBN 978-1-349-48566-6. OCLC 903145880. 
  8. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  9. "Psychoactive Substances" (PDF). National Drug and Alcohol Research Centre. 2014. [dead link]
  10. "Bundesrecht konsolidiert: Gesamte Rechtsvorschrift für Neue-Psychoaktive-Substanzen-Verordnung" (in Deutsch). June 26, 2019. Retrieved January 10, 2021. 
  11. "RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016" (in português). Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]. December 5, 2016. 
  12. "Schedule III". Controlled Drugs and Substances Act (CDSA). Isomer Design. Retrieved October 10, 2020. 
  13. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in 中文). 国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]. September 27, 2015. Archived from the original on September 6, 2017. 
  14. "Bekendtgørelse om euforiserende stoffer" (in dansk). Civilstyrelsen [Civil Agency]. May 31, 2011. BEK Nr. 557. Retrieved December 10, 2019. 
  15. "Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I" (in Deutsch). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  16. "Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF). Bundesgesetzblatt Jahrgang 2014 Teil I Nr. 57 (in Deutsch). Bundesanzeiger Verlag (published December 12, 2014). December 5, 2014. p. 1999-2002. ISSN 0341-1095. OCLC 231871244. 
  17. "Gesetz über den Verkehr mit Betäubungsmitteln: § 29" (in Deutsch). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  18. Uchiyama, N.; Kawamura, M.; Kamakura, H.; Kikura-Hanajiri, R.; Goda, Y. (2008). "Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical Affairs Law in Japan, Part I: GC-MS and LC-MS". Yakugaku Zasshi (in 日本語). 128 (6): 971–979. doi:10.1248/yakushi.128.981. eISSN 0031-6903. ISSN 1347-5231. OCLC 909890652. PMID 18520145. 
  19. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in latviešu). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020. 
  20. Wijziging van de Opiumwet in verband met het toevoegen van een derde lijst met als doel het tegengaan van de productie van en de handel in nieuwe psychoactieve stoffen en enkele andere wijzigingen (Dutch), 2024 
  21. "Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" (PDF). Läkemedelsverkets författningssamling (LVFS) (in svenska). Läkemedelsverket [Swedish Medical Products Agency] (published February 15, 2005). February 3, 2005. ISSN 1101-5225. SFS 2005:26. 
  22. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in Deutsch). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  23. Bakanlar Kurulu Kararı Karar Sayısı : 2013/4827 | https://free-ankara.org/wp-content/uploads/2017/09/BKK_2013_4827_28688.pdf
  24. "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020. 
  25. "S. 3187 (112th): Food and Drug Administration Safety and Innovation Act". GovTrack. June 27, 2012. Retrieved October 10, 2020.